United States - English - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - sodium chloride 0.9 g in 100 ml - potassium chloride in 0.9% sodium chloride injection is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. potassium chloride in 0.9% sodium chloride injection is contraindicated in clinical conditions where additives of sodium, potassium or chloride could be clinically detrimental.

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - potassium chloride 150 mg in 100 ml - potassium chloride in dextrose and sodium chloride injection is indicated as a source of water, electrolytes and calories. potassium chloride in dextrose and sodium chloride injection is contraindicated in patients with: risk summary appropriate administration of potassium chloride in dextrose sodium chloride injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with potassium chloride in dextrose sodium chloride injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary sodium and potassium are present in human breast milk. there are no data on the effects

Israel - English - Ministry of Health

eldan electronic instruments co ltd, israel - dextrose anhydrous; sodium chloride - solution for infusion - dextrose anhydrous 4.3 %w/v; sodium chloride 0.18 %w/v - sodium chloride - dextrose 4.3 % and 0.18 % sodium chloride vioser solution is used in the following indications: dehydration treatment due to a moderated loss of sodium and chloride (vomiting, diarrhoea, renal disorders, over use ofdiuretics) in cases where a source of energy is required (particularly starvation). paediatric population: this product should only be used in paediatric specialist settings (such as renal, hepatic and cardiac units, high dependency units and intensive care units) for intravenous fluid therapy requiring the use of 0.18% sodium chloride and4% glucose to maintain fluid and electrolyte balance.

United States - English - NLM (National Library of Medicine)

hospira, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0 - potassium chloride 1.79 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw need

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose hydrous (unii: lx22yl083g) (dextrose - unii:iy9xdz35w2), sodium chloride (unii: 451w47iq8x) (sodium chloride - unii:451w47iq8x), potassium chloride (unii: 660yq98i10) (potassium chloride - unii:660yq98i10), magnesium chloride (unii: 02f3473h9o) (magnesium chloride - unii:02f3473h9o), sodium gluconate (unii: r6q3791s76) (sodium gluconate - unii:r6q3791s76), sodium acetate (unii: 4550k0sc9b) (sodium acetate - unii:4550k0sc9b) - injection, solution - 5 g in 100 ml - plasma-lyte® 148 and 5% dextrose injection (multiple electrolytes and dextrose injection, type 1, usp) is indicated as a source of water, electrolytes, and calories, or as an alkalinizing agent. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

United States - English - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - dextrose monohydrate 5 g in 100 ml - intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient. none known. to open: tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. to add medication - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. preparation for administration (use aseptic technique) - close flow control clamp of administration set. - remove cover from outlet port at bottom of container. - insert piercing pin of administration set into port with a twisting motion until the set is firmly seated.

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride 1.5 g in 1.58 g - potassium chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on potassium sparing diuretics. pregnancy category c animal reproduction studies have not been conducted with potassium chloride. it is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity. the normal potassium ion content of human milk is about 13 meq per liter. since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. clinical trial data from published literature have demonstrated the safety and effectiveness of potassium chloride in children with diarrhea and malnutrition f

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - potassium chloride 150 mg in 100 ml - potassium chloride in dextrose injection is indicated as a source of water, electrolytes and calories. potassium chloride in dextrose injection is contraindicated in patients with: risk summary appropriate administration of potassium chloride in dextrose injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with potassium chloride in dextrose injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary potassium is present in human breast milk. there are no data on the effects of potassium chloride in dextrose injection on a breastfed infant or the effects on

Canada - English - Health Canada

baxter corporation - sodium chloride; potassium chloride - solution - 450mg; 150mg - sodium chloride 450mg; potassium chloride 150mg - replacement preparations

United States - English - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - dextrose monohydrate 50 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride with minimal carbohydrate calories and sodium chloride. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. preparation for admin